Literature DB >> 17723142

Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine.

A Undas, D Plicner, E Stepień, R Drwiła, J Sadowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17723142     DOI： 10.1111/j.1538-7836.2007.02637.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  12 in total

1.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 2.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

3.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

4.  Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.

Authors:  Yee Cheng Lau; Qinmei Xiong; Eduard Shantsila; Gregory Y H Lip; Andrew D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

Review 5.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

6.  Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties.

Authors:  Anna Aleksandra Skuza; Maciej Polak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2019-01       Impact factor: 2.300

7.  Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Authors:  Søs Neergaard-Petersen; Ramzi Ajjan; Anne-Mette Hvas; Katharina Hess; Sanne Bøjet Larsen; Steen Dalby Kristensen; Erik Lerkevang Grove
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

8.  Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Maria Bertilsson; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Eur Heart J       Date:  2018-04-01       Impact factor: 29.983

9.  Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.

Authors:  Joanna Żuk; Agnieszka Snarska-Drygalska; Krzysztof Piotr Malinowski; Elżbieta Papuga-Szela; Joanna Natorska; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

10.  Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Thromb Haemost       Date:  2020-01-23       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.